184 related articles for article (PubMed ID: 34624648)
1. Clinicopathological and computed tomographic features associated with occult lymph node metastasis in patients with peripheral solid non-small cell lung cancer.
He XQ; Luo TY; Li X; Huo JW; Gong JW; Li Q
Eur J Radiol; 2021 Nov; 144():109981. PubMed ID: 34624648
[TBL] [Abstract][Full Text] [Related]
2. Tumour-pleura relationship on CT is a risk factor for occult lymph node metastasis in peripheral clinical stage IA solid adenocarcinoma.
Zhang C; Wang L; Cai X; Li M; Sun D; Wang P
Eur Radiol; 2023 May; 33(5):3083-3091. PubMed ID: 36806570
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Kaseda K; Asakura K; Kazama A; Ozawa Y
World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
[TBL] [Abstract][Full Text] [Related]
4. [Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery].
Wang X; Zheng L; Zhang SY; Xie ZM; Yu H; Su XD; Wang JY; Huang ZF; Yang MT; Rong TH
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):456-9. PubMed ID: 19950559
[TBL] [Abstract][Full Text] [Related]
5. Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer.
Park SY; Yoon JK; Park KJ; Lee SJ
Cancer Imaging; 2015 Dec; 15():21. PubMed ID: 26694918
[TBL] [Abstract][Full Text] [Related]
6. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
[TBL] [Abstract][Full Text] [Related]
7. Predicting occult lymph node metastasis by nomogram in patients with lung adenocarcinoma ≤2 cm.
Wang Z; Wu Y; Wang L; Gong L; Han C; Liang N; Li S
Future Oncol; 2021 Jun; 17(16):2005-2013. PubMed ID: 33784826
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography characteristics of cN0 primary non-small cell lung cancer predict occult lymph node metastasis.
Yoon DW; Kang D; Jeon YJ; Lee J; Shin S; Cho JH; Choi YS; Zo JI; Kim J; Shim YM; Cho J; Kim HK; Lee HY
Eur Radiol; 2024 Jun; ():. PubMed ID: 38850308
[TBL] [Abstract][Full Text] [Related]
9. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
Shi YM; Niu R; Shao XL; Zhang FF; Shao XN; Wang JF; Wang XS; Liu B; Yu WJ; Wang YT
Nucl Med Commun; 2020 May; 41(5):459-468. PubMed ID: 32187163
[TBL] [Abstract][Full Text] [Related]
10. [Potential value of FDG PET-CT in predicting occult lymph node metastasis in clinical stage ⅠA lung adenocarcinoma].
Lyu L; Liu Y; Wang XY; Zhang ZK; Tao XL; Yang L; Wu N
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):441-447. PubMed ID: 31216830
[No Abstract] [Full Text] [Related]
11. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.
Yeh YC; Kadota K; Nitadori J; Sima CS; Rizk NP; Jones DR; Travis WD; Adusumilli PS
Eur J Cardiothorac Surg; 2016 Jan; 49(1):e9-e15. PubMed ID: 26377636
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Contrast-Enhanced CT and Clinicopathological Characteristics and Prognosis of Non-Small Cell Lung Cancer.
Yang H; Fan HX; Song LH; Xie JC; Fan SF
Oncol Res Treat; 2017; 40(9):516-522. PubMed ID: 28866685
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological features associated with skip N2 metastases in patients with clinical stage IA non-small-cell lung cancer.
Gorai A; Sakao Y; Kuroda H; Uehara H; Mun M; Ishikawa Y; Nakagawa K; Masuda M; Okumura S
Eur J Cardiothorac Surg; 2015 Apr; 47(4):653-8. PubMed ID: 24957260
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of dual energy CT for lymph node metastasis in patients with non-small cell lung cancer].
Kuang P; Ding X; Xu J; Zhou Q; Zhang M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 May; 46(5):511-516. PubMed ID: 29488718
[TBL] [Abstract][Full Text] [Related]
15. [Comparative imaging study of mediastinal lymph node from pre-surgery dual energy CT
Zhu Q; Ren C; Zhang Y; Li MJ; Wang XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):730-737. PubMed ID: 32773811
[TBL] [Abstract][Full Text] [Related]
16. Occult lymph node metastasis is not a favorable factor for resected NSCLC patients.
Cai JS; Yang F; Wang X
BMC Cancer; 2023 Sep; 23(1):822. PubMed ID: 37667180
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.
Liu Y; Kim J; Balagurunathan Y; Hawkins S; Stringfield O; Schabath MB; Li Q; Qu F; Liu S; Garcia AL; Ye Z; Gillies RJ
Med Phys; 2018 Jun; 45(6):2518-2526. PubMed ID: 29624702
[TBL] [Abstract][Full Text] [Related]
19. Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.
Akthar AS; Ferguson MK; Koshy M; Vigneswaran WT; Malik R
Technol Cancer Res Treat; 2017 Feb; 16(1):15-21. PubMed ID: 26792491
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.
Seol HY; Kim YS; Kim SJ
Oncology; 2021; 99(2):96-104. PubMed ID: 32980838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
